登录 查看组织和合同定价。
选择规格
变更视图
关于此项目
经验公式(希尔记法):
C24H20F4N2O3
化学文摘社编号:
分子量:
460.42
UNSPSC Code:
12352202
MDL number:
NACRES:
NA.21
Assay:
≥98% (HPLC)
Form:
powder
Quality Segment
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear (Warmed)
storage temp.
2-8°C
SMILES string
O=C1C2=C(CN1C3=CC=C(C(C)(C)O)C=C3)C(C4=C(OCC(F)(F)F)C=C(F)C=C4)=NC=C2
InChI key
OAZAPIKYVGRNCO-UHFFFAOYSA-N
Biochem/physiol Actions
Orally active, brain-penetrant, substrate-noncompetitive glucosylceramide synthase (GCS) inhibitor with therapeutic efficacy in a murine Gaucher’s disease (GD) model in vivo.
TP-060 (T-036) is an orally active, brain-penetrant, substrate-noncompetitive, potent and selective glucosylceramide synthase (GCS) inhibitor (human/mouse IC50 = 31/51 nM) that effectively downregulates glucosylceramide (GlcCer) level in GBA mutant human fibroblasts containing mutated glucosylceramidase (IC50 = 7.6 nM). TP-060 is efficacious in lowering both GlcCer and glucosylsphingosine (GlcSph) levels in the plasma and cerebral cortex of Gba D409V KI mice in vivo following a two-month treatment in the murine Gaucher’s disease (GD) model (10 and 30 mg/kg/day p.o.).
TP-060 (T-036) is an orally active, brain-penetrant, substrate-noncompetitive, potent and selective glucosylceramide synthase (GCS) inhibitor (human/mouse IC50 = 31/51 nM) that effectively downregulates glucosylceramide (GlcCer) level in GBA mutant human fibroblasts containing mutated glucosylceramidase (IC50 = 7.6 nM). TP-060 is efficacious in lowering both GlcCer and glucosylsphingosine (GlcSph) levels in the plasma and cerebral cortex of Gba D409V KI mice in vivo following a two-month treatment in the murine Gaucher’s disease (GD) model (10 and 30 mg/kg/day p.o.).
存储类别
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable